Detalles de la búsqueda
1.
Combination with a FtsZ inhibitor potentiates the in vivo efficacy of oxacillin against methicillin-resistant Staphylococcus aureus.
Med Chem Res
; 31(10): 1705-1715, 2022 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-37065467
2.
Development and Preclinical Evaluation of New Inhaled Lipoglycopeptides for the Treatment of Persistent Pulmonary Methicillin-Resistant Staphylococcus aureus Infections.
Antimicrob Agents Chemother
; 65(7): e0031621, 2021 06 17.
Artículo
en Inglés
| MEDLINE | ID: mdl-33941518
3.
Correction for Plaunt et al., "Development and Preclinical Evaluation of New Inhaled Lipoglycopeptides for the Treatment of Persistent Pulmonary Methicillin-Resistant Staphylococcus aureus Infections".
Antimicrob Agents Chemother
; 66(11): e0125622, 2022 Nov 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-36222535
4.
Combining the FtsZ-Targeting Prodrug TXA709 and the Cephalosporin Cefdinir Confers Synergy and Reduces the Frequency of Resistance in Methicillin-Resistant Staphylococcus aureus.
Antimicrob Agents Chemother
; 60(7): 4290-6, 2016 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-27161635
5.
TXA709, an FtsZ-Targeting Benzamide Prodrug with Improved Pharmacokinetics and Enhanced In Vivo Efficacy against Methicillin-Resistant Staphylococcus aureus.
Antimicrob Agents Chemother
; 59(8): 4845-55, 2015 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-26033735
6.
An FtsZ-targeting prodrug with oral antistaphylococcal efficacy in vivo.
Antimicrob Agents Chemother
; 57(12): 5860-9, 2013 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-24041882
7.
Structural and Antibacterial Characterization of a New Benzamide FtsZ Inhibitor with Superior Bactericidal Activity and In Vivo Efficacy Against Multidrug-Resistant Staphylococcus aureus.
ACS Chem Biol
; 18(3): 629-642, 2023 03 17.
Artículo
en Inglés
| MEDLINE | ID: mdl-36854145
8.
The pharmacokinetic profile of brensocatib and its effect on pharmacodynamic biomarkers including NE, PR3, and CatG in various rodent species.
Front Pharmacol
; 14: 1208780, 2023.
Artículo
en Inglés
| MEDLINE | ID: mdl-37538173
9.
Loss of retrograde endocannabinoid signaling and reduced adult neurogenesis in diacylglycerol lipase knock-out mice.
J Neurosci
; 30(6): 2017-24, 2010 Feb 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-20147530
10.
Monoacylglycerol lipase activity is a critical modulator of the tone and integrity of the endocannabinoid system.
Mol Pharmacol
; 78(6): 996-1003, 2010 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-20855465
11.
Pharmacological and pharmacokinetic characterization of the cannabinoid receptor 2 agonist, GW405833, utilizing rodent models of acute and chronic pain, anxiety, ataxia and catalepsy.
Neuropharmacology
; 48(5): 658-72, 2005 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-15814101
12.
A role for cannabinoid receptors, but not endogenous opioids, in the antinociceptive activity of the CB2-selective agonist, GW405833.
Eur J Pharmacol
; 528(1-3): 65-72, 2005 Dec 28.
Artículo
en Inglés
| MEDLINE | ID: mdl-16316650
13.
Pharmacological characterisation of a rat model of incisional pain.
Br J Pharmacol
; 141(1): 85-91, 2004 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-14597606
14.
Pharmacokinetics and in vivo antistaphylococcal efficacy of TXY541, a 1-methylpiperidine-4-carboxamide prodrug of PC190723.
Biochem Pharmacol
; 86(12): 1699-707, 2013 Dec 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-24148278
15.
Discovery of novel selective norepinephrine inhibitors: 1-(2-morpholin-2-ylethyl)-3-aryl-1,3-dihydro-2,1,3-benzothiadiazole 2,2-dioxides (WYE-114152).
J Med Chem
; 54(19): 6824-31, 2011 Oct 13.
Artículo
en Inglés
| MEDLINE | ID: mdl-21916421
16.
Pain is a salient "stressor" that is mediated by corticotropin-releasing factor-1 receptors.
Neuropharmacology
; 59(3): 160-6, 2010 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-20470804
17.
1- or 3-(3-Amino-2-hydroxy-1-phenyl propyl)-1,3-dihydro-2H-benzimidazol-2-ones: potent, selective, and orally efficacious norepinephrine reuptake inhibitors.
J Med Chem
; 52(18): 5703-11, 2009 Sep 24.
Artículo
en Inglés
| MEDLINE | ID: mdl-19722525
18.
Pharmacology of 2-[4-(4-chloro-2-fluorophenoxy)phenyl]-pyrimidine-4-carboxamide: a potent, broad-spectrum state-dependent sodium channel blocker for treating pain states.
J Pharmacol Exp Ther
; 318(3): 1083-93, 2006 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-16728593
19.
N-(4-Tertiarybutylphenyl)-4-(3-cholorphyridin-2-yl)tetrahydropyrazine -1(2H)-carbox-amide (BCTC), a novel, orally effective vanilloid receptor 1 antagonist with analgesic properties: II. in vivo characterization in rat models of inflammatory and neuropathic pain.
J Pharmacol Exp Ther
; 306(1): 387-93, 2003 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-12721336
20.
DiPOA ([8-(3,3-diphenyl-propyl)-4-oxo-1-phenyl-1,3,8-triazaspiro[4.5]dec-3-yl]-acetic acid), a novel, systemically available, and peripherally restricted Mu opioid agonist with antihyperalgesic activity: II. In vivo pharmacological characterization in the rat.
J Pharmacol Exp Ther
; 310(2): 793-9, 2004 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-15054116
Resultados
1 -
20
de 20
1
Próxima >
>>